Oppenheimer Maintained Perform on GoPro (GPRO) After Meeting with Management
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Citi Sees Weak Near-Term Results for GoPro (GPRO) But Says Concerns Priced In
September 17, 2015 9:04 AM EDTCiti analysts are cutting near-term estimates on GoPro (NASDAQ: GPRO) but reiterated a Buy rating and $90 price target on GoPro (NASDAQ: GPRO), saying weak Q3 and Q4 results are largely priced in and HERO4 concerns create an attractive entry point.
The analysts noted that CFO Lazar confirmed at... More
GoPro (GPRO) Gains as Two Bullish Pieces Embolden Investors
September 14, 2015 12:10 PM EDTAfter seeing tremendous pressure over the past few weeks, shares of GoPro (NASDAQ: GPRO) are up 4.4% Monday, benefiting from two items: 1. The WSJ posted a bullish-leaning Heard on the Street Column "Shredded GoPro Finally Looks Like a Deal"; 2. Northland... More
Pre-Open Stock Movers 09/14: (COLL) (AQXP) (SLH) Higher; (RPTP) (BABA) (GOLD) Lower (more...)
September 14, 2015 9:23 AM EDTCollegium Pharmaceutical, Inc. (NASDAQ: COLL) 33% HIGHER; confirmed late Friday that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted unanimously to support the approval of Xtampza ER (oxycodone extended-release capsules) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Raptor Pharma (NASDAQ: RPTP) 27.4% LOWER; announced topline... More
GoPro's (GPRO) Addressable Market Seen at ~$20B
September 14, 2015 6:47 AM EDTGoPro (Nasdaq: GPRO) shares are on watch following mixed commentary in the WSJ over the weekend.
The WSJ noted recent... More
